国际肿瘤学杂志

国际肿瘤学杂志 ›› 2019, Vol. 46 ›› Issue (11): 695-698.doi: 10.3760/cma.j.issn.1673-422X.2019.11.011

• 综述 • 上一篇    下一篇

PD-1/PD-L1抑制剂在小细胞肺癌中的研究及应用

吴文娟，李桂香，杜明丽，赵磊   

  1. 兰州大学第二医院伽马刀治疗科730030
  • 出版日期:2019-11-08 发布日期:2019-12-26
  • 通讯作者: 李桂香 E-mail:lgx.doctor.007@163.com
  • 基金资助:
    国家自然科学基金(81670594)

Research and application of PD-1/PD-L1 inhibitors in small cell lung cancer

Wu Wenjuan, Li Guixiang, Du Mingli, Zhao Lei   

  1. Department of Gamma Knife Therapy, Second Hospital of Lanzhou University, Lanzhou 730030, China
  • Online:2019-11-08 Published:2019-12-26
  • Contact: Li Guixiang E-mail:lgx.doctor.007@163.com
  • Supported by:
    National Natural Science Foundation of China (81670594)

PDF

318

摘要： 小细胞肺癌（SCLC）是恶性程度极高的侵袭性神经内分泌癌。目前，SCLC的标准治疗仍是放化疗，虽然SCLC早期对化疗敏感，但往往因耐药而出现复发转移。近年来，免疫治疗在SCLC的研究中取得了一定的进展，免疫检测点程序性死亡受体-1（PD-1）及其配体（PD-L1）抑制剂，如纳武单抗、阿特珠单抗、帕博利珠单抗等，在SCLC的临床研究中显示出良好的抗肿瘤活性，且PD-1/PD-L1抑制剂联合化疗显示出了更好的疗效，为SCLC的治疗提供了新的策略。

关键词: 小细胞肺癌, 免疫疗法, PD-1/PD-L1

Abstract: Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a very high degree of malignancy. Currently, the standard treatment for SCLC is still chemoradiotherapy, and although SCLC is sensitive to chemotherapy in the early stage, recurrence and metastasis often occur due to drug resis-tance. In recent years, immunotherapy has made some progress in the study of SCLC. The immunodetection point programmed death-1 (PD-1) and its ligand (PD-L1) inhibitors, such as nivolumab, atezolizumab and pabolizumab, have shown good antitumor activity in clinical studies of SCLC, and PD-1/PD-L1 inhibitors combined with chemotherapy have shown better efficacy, providing a new strategy for the treatment of SCLC.

Key words: Small cell lung carcinoma, Immunotherapy, PD-1/PD-L1